Florida / New York

A Publication for the Practicing Medical Specialist, Industry Executive & Investor

Apyx Medical Corporation Launches its Latest-generation Renuvion Generator, the Apyx One Console, in the United States

Apyx Medical notes Apyx One Console is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy. 

Apyx Medical Corporation, the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of its latest-generation Renuvion generator, the Apyx One Console, in the United States.

The Apyx One Console is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy.

Key features of the Apyx One Console include adaptive and intuitive touch screens, procedural presets by body part, cloud connectivity, data sharing and logging, remote upgrade capabilities and system diagnostics, and an advanced gas system that measures and monitors gas volume and usage.

For video of the new Renuvion generator visit:  bhttps://www.youtube.com/watch?v=7-KTTq8EnQ8

Four years in the making, the design, development, and testing of the Apyx One Console was led by the Company’s product development team, who collaborated with the following physicians to guide and validate the product design and usability requirements: Dr. John Frederick, Dr. Michael Kluska, Dr. Adam Rubinstein and Dr. Drew Schnitt.

The full system is available to physicians throughout the U.S. and comes with an industry-leading 4-year warranty. An upgrade program is available for current Apyx customers who would like to exchange their current system for the new Apyx One Console.

Share:

More Posts

Alithea Genomics Launches MERCURIUS™ Total DRUG-seq: A Next-Generation Full-Length Transcriptome Profiling Platform for High-Throughput Compound Screening and Target Validation

“MERCURIUS™ Total DRUG-seq represents a new frontier in transcriptome-scale compound screening,” said Riccardo Dainese, CEO and Co-founder of Alithea Genomics. “We are empowering scientists to capture the full complexity of transcriptional responses—at a massive scale and with minimal cost. This product opens the door to discovering new biology, new targets, and new drugs faster than ever before.”

Send Us A Message